

What Is Claimed Is:

*Subj 2* 1. A conjugate of a non-immunogenic toxin or therapeutic radionuclide and a cell-specific cytokine.

*2.* 2. A conjugate as claimed in claim 1, wherein said toxin is an RNase.

*2b.* 3. A conjugate as claimed in claim 1, wherein said cytokine is IL-15.

*Mr Col 4.* 4. A conjugate as claimed in claim 3, wherein said toxin is onconase.

*5.* 5. A conjugate as claimed in claim 4, which additionally comprises a diagnostic radionuclide.

*6.* 6. A composition comprising a conjugate according to claim 1, and a pharmaceutically acceptable carrier.

*7.* 7. A composition as claimed in claim 6, additionally comprising a diagnostic radionuclide conjugated to said cytokine.

*8.* 8. A fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 $\alpha$ .

*9.* 9. A fusion protein as claimed in claim 8, wherein said bispecific antibody is a scF<sub>v</sub>.

*10.* 10. A fusion protein as claimed in claim 9, wherein said scF<sub>v</sub> is a fusion of two individual scF<sub>v</sub> molecules.

*11.* 11. A fusion protein as claimed in claim 8, wherein said cell marker is a B-cell restricted antigen.

~~11~~  
~~12~~ A fusion protein as claimed in claim ~~11~~, wherein said cell marker is CD20.

~~13~~  
~~14~~ A fusion protein as claimed in claim ~~8~~, wherein said region of IL-15 $\alpha$  is an extracellular domain of IL-15 $\alpha$ .

~~15~~  
~~16~~ A composition comprising a fusion protein according to claim ~~8~~ and a pharmaceutically acceptable carrier.

~~17~~  
~~18~~ 15. A kit comprising a conjugate of onconase and IL-15, and a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 $\alpha$ .

16. A method of treating a malignancy, comprising the steps of: first administering to a subject having a malignancy a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 $\alpha$ , and then administering to said subject therapeutically effective amount of a conjugate of onconase and IL-15.

17. A method as claimed in claim 16, additionally comprising a step of administering at least one of chemotherapy and radiation therapy in an amount sufficient to prevent tumor cells from activating DNA-repair mechanisms.

18. A method as claimed in claim 16, wherein said cell marker is a B-cell restricted antigen and said subject has a B-cell malignancy.

19. A method as claimed in claim 18, wherein said cell marker is CD20 and said subject has B-cell lymphocytic leukemia, non-Hodgkin's lymphoma, hairy cell leukemia or acute myelogenous leukemia.

~~Add a4~~

11